Incyte Corporation INCY
122.27 USD 0.00 (+0.00%)
At closeNov 12, 2026, 9:20 AM EST
122.92 +0.65 +0.53%
Pre-market · Nov 12, 9:20 AM ET
117.84 Day range 122.73
89.25 52-week range 132.60
- YTD
- +23.79%
- 1 year
- +13.05%
News
marketbeat.com Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030 Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as…
seekingalpha.com Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
benzinga.com Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatmentNatera, Inc. (NASDAQ:NTRA), a global leader in…
businesswire.com Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with…
businesswire.com 2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the…
benzinga.com Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150 Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $154 to $150.
benzinga.com $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 17.11%. Currently, Incyte has a market capitalization of…
defenseworld.net Incyte Corporation $INCY Shares Newly Purchased by Compass Financial Management LLC Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the…
benzinga.com Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology…
benzinga.com Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108 Bernstein analyst Jeffrey Walch maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $104 to $108.
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.- benzinga.com Barclays Maintains Overweight on Incyte, Raises Price Target to $143 Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.- benzinga.com Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127 Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.- benzinga.com Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144 Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
benzinga.com Incyte Q3 2026 Earnings Call Transcript Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $5.130 billion-$5.260 billion to $5.210 billion-$5.300 billion vs $5.929 billion estimate.- benzinga.com Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate Incyte (NASDAQ:INCY) reported quarterly losses of $(3.60) per share which beat the analyst consensus estimate of $(3.85) by 6.49 percent. This is a 259.29 percent decrease over earnings of $2.26 per…
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.- benzinga.com TD Cowen Maintains Buy on Incyte, Raises Price Target to $140 TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.
benzinga.com Why Is Arcutis Biotherapeutics Stock Surging Thursday? Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.- benzinga.com Truist Securities Maintains Hold on Incyte, Raises Price Target to $115 Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.
- benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.
benzinga.com If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of…- benzinga.com Stifel Maintains Buy on Incyte, Raises Price Target to $157 Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.
benzinga.com If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of…
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.- benzinga.com JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123 JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
benzinga.com FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
benzinga.com Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.- benzinga.com HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.
- benzinga.com RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.
- benzinga.com Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3 Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic…
benzinga.com Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
benzinga.com Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’ CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.
benzinga.com This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.- benzinga.com Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of…
benzinga.com Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of…
benzinga.com Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152 Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.- benzinga.com HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
- benzinga.com Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130 Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
- benzinga.com Mizuho Maintains Outperform on Incyte, Raises Price Target to $137 Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $121 to $137.
benzinga.com Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.- benzinga.com Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155 Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $131 to $155.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
- benzinga.com Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the…
- benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $99 to $109.